China's Universities and Pharma: A Change In Power Balance?
This article was originally published in PharmAsia News
Executive Summary
China's pharma companies may one day soon find themselves without the R&D support of the country's leading universities, and companies have the country's push to improve IP protection to thank
You may also be interested in...
Early Days For Discovery Collaborations With Academia In China - China Healthcare Investment Conference
BEIJING - Big Pharma and device companies are looking to test different models to harness a new source of novel technology as China's innovative life science sectors become more developed. Returnees, Chinese researchers and entrepreneurs that study or work in the West before establishing or working for companies in China, may have a large impact on how Western firms approach partnering in China
Early Days For Discovery Collaborations With Academia In China - China Healthcare Investment Conference
BEIJING - Big Pharma and device companies are looking to test different models to harness a new source of novel technology as China's innovative life science sectors become more developed. Returnees, Chinese researchers and entrepreneurs that study or work in the West before establishing or working for companies in China, may have a large impact on how Western firms approach partnering in China
Novartis Lines Up $1 Billion For China R&D
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space